methods. We present a case of 28-year old woman suffering from POF due to chemotherapy of the Hodgkin lymphoma (HL) who became pregnant spontaneously during hormonal substitution treatment. Case report. A young woman was diagnosed with HL in September 2006. The condition was identified at the clinical stage IIIB and treated with 4 cycles of ABVD chemotherapy. During chemotherapy, the patient was treated with gonadotropine analogues (GnRH-a) to prevent development of POF. Unfortunately, HL relapsed after nearly a year (August 2007) required treatment with salvage (DHAP regimen) and subsequently high-dose chemotherapy (BEAM regimen) with autologous stem cell transplantation. This treatment resulted in POF despite supportive concomitant treatment with GnRH-a. The patient was treated with combined hormonal replacement therapy from May 2008. Two years after the second line oncology treatment, the patient became pregnant spontaneously. Considering the anamnesis of her own 2 healthy children, she decided to undergo termination of her pregnancy. Discussion and conclusion. Chemotherapy accelerates atresia of the ovarian follicles. The exact mechanism of its gonadotoxic effect is unknown. POF develops due to the loss of all ovarian follicles containing fetal cells and the likelihood of spontaneous conception is very low. Animal studies have demonstrated the possibility of neo-folliculogenesis of fetal cells from pluripotent bone marrow stem cells, which migrate into the ovary. The case of spontaneous conception described above contradicts the theory of predetermined number of fetal cells in woman’s ovary. Our case report demonstrates that POF induces by chemotherapy does not need to be permanent.

P143
IS INTENSIFICATION OF THERAPY IN HL PET2+ PATIENTS REALLY USEFUL?
Sancetta R,1 Rigacci L,1 Puccini B,1 Pregno P,1 Vitolo U,1 Brusamolino E,1 Gotti M,2 Magagnoli M,2 Carella AM,3 Rossi E,3 Gallamini A,1 Chiesi T1 U.O. di Ematologia, Ospedale dell’Angelo, Venezia-Mestre; SOD Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze; S.C.D.O. Ematologia 2, A.O.U. S. Giovanni Battista – Torino; Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia; Dipartimento di Oncologia medica ed Ematologia - Istituto Clinico Humanitas-Rozzano (MI); Divisione di Ematologia 2, Ospedale S. Martino, Genova; Hematology Department Az. Ospedaliera S. Croce e Carlo, Cuneo, Italy

Background. As reported from recent studies, PET2- in patients with HL is an important prognostic factor and a positive predictive value for survival. In order to analyze the feasibility of a prospective randomized study based on early intensification would be evaluated retrospectively the outcome of HL pts with PET2+ treated with ASCT as intensification compared with a group of patients conventionally treated. The characteristics of the two groups of patients were homogeneous in terms of clinical features and risk factors. Methods. Fifty-seven pts with Hodgkin Lymphoma (HL) and a PET2+, from different Italian centres, were examined: 23 M and 34 F, male/female distribution –16/31. The utility of CSP-Lym was demonstrated by comparison of symptom severity before and after treatment. The construct validity of CSP-Lym was proved by factor analysis and “known-group” comparison. Statistically significant differences (P<0.05) in symptom severity were found in the groups with/without B symptoms: 60% of symptoms were more severe in patients with B symptoms as compared with the group without B symptoms. Sensitivity to changes was demonstrated by comparison of symptom severity before and after treatment. Thus, CSP-Lym is an appropriate and practical tool to assess the symptom severity in patients with HL. The utility of the questionnaire was shown; preliminary psychometric properties appeared to be satisfactory. Further studies are needed before the wide-spread use of CSP-Lym in clinical practice and clinical trials in this patient population.

P144
THE USE OF FDG POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN PATIENTS WITH HODGKIN LYMPHOMA (HL) IN THE “REAL WORLD”: A POPULATION BASED STUDY FROM NORTHERN ITALY
Luminari S,1 Postiglione R,1 Mangone L,4 Versari A,5 Re F,6 De Lisi V,7 Ruffini L,8 Sancetta R,1 Riggio L,1 Puccini B,1 Pregno P,1 Vitolo U,1 Brusamolino E,1 Gotti M,2 Magagnoli M,2 Carella AM,3 Rossi E,3 Gallamini A,1 Chiesi T1 U.O. di Ematologia, Ospedale dell’Angelo, Venezia-Mestre; Divisione di Ematologia 2, Ospedale S. Martino, Genova; Dipartimento di Oncologia medica ed Ematologia - Istituto Clinico Humanitas-Rozzano (MI); Department of Oncology - Azienda Ospedaliero Universitaria Careggi, Firenze; Dipartimento di Oncologia ed Ematologia - Ospedale S. Maria Nuova, Reggio Emilia; Dipartimento di Oncologia ed Ematologia, Università di Modena e Reggio Emilia, Modena; Ematologia, A.O. S.M. Nuova, Reggio Emilia; Registro Tumori di Reggio Emilia.

Comprehensive assessment of symptoms during and after treatment in Hodgkin's Lymphoma (HL) patients is of great value. The goal of this study was to test the applicability of a new symptom assessment tool – Comprehensive Symptom Profile in Lymphoma Patients (CSP-Lym) in patients with HL. CSP-Lym is being developed to assess the severity of 45 symptoms specific for lymphoma patients. It consists of numerical rating scales, scored from “0” (no symptom) to “10” (most expressed symptom). Six clusters of symptoms have been identified, which were clinically relevant and increased the practicability of the tool. Applicability of CSP-Lym in HL patients was investigated. The presence of psychometric properties was tested in a pilot study. 47 HL patients (Stage I-II, n=34; Stage III-IV, n=13) were included in the study. Mean age was 28.7 years old, male/female distribution –16/31. The utility of CSP-Lym was demonstrated: all the items were easy for the patients to read and understand; the data produced by the tool were clear for interpretation by physicians and were used by them in clinical decision making. Reliability of CSP-Lym was satisfied (Chrombach’s alpha coefficient varied from 0.74 to 0.94). The construct validity of CSP-Lym was proved by factor analysis and “known-group” comparison. Statistically significant differences (P<0.05) in symptom severity were found in the groups with/without B symptoms: 60% of symptoms were more severe in patients with B symptoms as compared with the group without B symptoms. Sensitivity to changes was demonstrated by comparison of symptom severity before and after treatment. Thus, CSP-Lym is an appropriate and practical tool to assess the symptom severity in patients with HL. The utility of the questionnaire was shown; preliminary psychometric properties appeared to be satisfactory. Further studies are needed before the wide-spread use of CSP-Lym in clinical practice and clinical trials in this patient population.
FDG-PET is currently used in patients with HL. Radiotherapy improves early stage pts outcome in a combined modality protocol. No statistical significance in this small cohort, seems to predict EFS. Presence of B symptoms, bulky mass and extra-nodal disease correlated to RFS (P=0.0314, P=0.0076 and P=0.0058). Interim PET was positive in 10,3% and 32% of localized and advanced stages, respectively. Interim PET positivity showed a borderline correlation with RFS (P=0.057) (Figure 1). No correlation was found between residual mass of any size at final CT and RFS (P=0.746) (Figure 2). RT was associated with longer EFS in early stage pts (P=0.032). Conclusion. This analysis confirms the unfavourable prognostic value of B symptoms, bulky disease and extra-nodal involvement at diagnosis of classical HL. Interim PET, even if it didn't reach statistical significance in this small cohort, seems to predict EFS. Presence of a residual mass at final CT didn't correlate with RFS, irrespectively to size. Radiotherapy improves early stage pts outcome in a combined modality and should not be omitted outside of clinical trials.

**P145**

**BASELINE AND DYNAMIC PROGNOSTIC FACTORS IN NEWLY DIAGNOSED CLASSICAL HODGKIN’S LYMPHOMA**

Rusconi C, Ravelli E, Gabutti C, Zilioli V, Meli E, Nichelli M, Gargantini L, Morra E

Division of Hematology and Bone Marrow Transplantation, Niguarda Hospital, Milan, Italy

**Introduction.** Classical Hodgkin’s lymphoma (HL) is a highly curable disease; nevertheless a minor but not negligible part of patients (pts) is refractory to treatment or relapses. We retrospectively analyzed 105 consecutive HL pts in the attempt to identify characteristics, both at baseline and during therapy, predicting for outcome in terms of overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS).

**Patients and Methods.** Median age at diagnosis was 36 years; 46 pts were male. Stage at presentation was localized in 62 pts (59%) and advanced in 43 pts (41%). B symptoms were registered in 45 cases (42,8%), a bulky mass in 30 pts (28,6%) and extra-nodal involvement in 36 pts (34,3%). Pts were treated with 3 to 8 ABVD cycles according to stage and involved-field radiotherapy (RT) was delivered to 24/62 early stage pts (38,9%). Pts underwent interim PET after 2 cycles. Final restaging consisted of both CT and PET. Therapeutic plan was completed irrespectively to interim PET outcome. **Results.** After a median follow-up of 36 months median OS was not reached, while EFS was 80.5 months. Complete response was obtained in 81 pts (77,1%), partial response in 9 pts (8,6%), while stable or progressive disease was observed in 15 pts (14,3%). Presence of B symptoms, bulky mass and extra-nodal disease correlated to RFS (P=0.0014, P=0.0076 and P=0.0058). Interim PET was positive in 10,3% and 32% of localized and advanced stages, respectively. Interim PET positivity showed a borderline correlation with RFS (P=0.057) (Figure 1). No correlation was found between residual mass of any size at final CT and RFS (P=0.746) (Figure 2). RT was associated with longer EFS in early stage pts (P=0.032). Conclusion. This analysis confirms the unfavourable prognostic value of B symptoms, bulky disease and extra-nodal involvement at diagnosis of classical HL. Interim PET, even if it didn't reach statistical significance in this small cohort, seems to predict EFS. Presence of a residual mass at final CT didn’t correlate with RFS, irrespectively to size. Radiotherapy improves early stage pts outcome in a combined modality and should not be omitted outside of clinical trials.

**P146**

**THIRD TUNISIAN PROSPECTIVE MULTICENTER STUDY FOR ADULT HODGKIN LYMPHOMA (HL): MDH 2008 PRELIMINARY EVALUATION OF THE RESULTS**


Tunisian Adult Hodgkin Lymphoma Study Group, Tunisia

The High rate of relapse: 23% in favorable(fav)advanced HL(IFS<3,treated by 8ABVD) and the adverse prognostic factor of bulky mediastinal mass were the major issues detected in the second Tunisian prospective study (MDH2002). The third prospective study (MDH2008) was opened in July 2008 with the main objectives to improve EFS in patients with unfavorable HL (Gr3:stage I with bulky mediastinum, III–IV), to reduce toxicity in patients with favorable HL (Gr1: Fav stage II according to EORTC criteria) and intermediate HL (Gr2: Unfav stage I-II with no bulky mediastinum). Patients. From July 2008 to December 2009, 80 eligible patients (pts) with HL were enrolled to the MDH2008 in four centers. 73 pts with median age of 26 years (16-73 y) and a sex-ratio of 0.78 (32M/41F) were evaluable. Advanced stages were present at diagnosis in 54.2% of cases, 68.5% of our pts were B and 38% had a bulky mediastinal mass. Methods. Gr1 pts (5.5% of pts) in complete response (CR=75%), after 2ABVD received 3Gy involved field (IF) radiotherapy (RT). If partial response (PR) after initial 2ABVD, pts receive one